4.7 Article

A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223

Journal

EUROPEAN HEART JOURNAL
Volume 37, Issue 33, Pages 2602-U24

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv713

Keywords

Circular RNA; HRCR; Cardiac hypertrophy; Heart failure

Funding

  1. National Natural Science Foundation of China [81270160, 81470522, 81522005]
  2. Beijing Natural Science Foundation [7142103]

Ask authors/readers for more resources

Our present study reveals a novel cardiac hypertrophic regulating model that is composed of circRNA, miR-223, and ARC. Modulation of their levels may provide a new approach for tackling cardiac hypertrophy and heart failure. Our present work advances our understanding about the role of circRNAs and miRNAs in cardiac hypertrophy and heart failure. Circular RNA may represent a potential new therapeutic strategy to attenuate the pathogenesis of cardiac diseases.Sustained cardiac hypertrophy accompanied by maladaptive cardiac remodelling represents an early event in the clinical course leading to heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. However, the molecular mechanisms that regulate cardiac hypertrophy are largely unknown. Here we show that a circular RNA (circRNA), which we term heart-related circRNA (HRCR), acts as an endogenous miR-223 sponge to inhibit cardiac hypertrophy and heart failure. miR-223 transgenic mice developed cardiac hypertrophy and heart failure, whereas miR-223-deficient mice were protected from hypertrophic stimuli, indicating that miR-223 acts as a positive regulator of cardiac hypertrophy. We identified ARC as a miR-223 downstream target to mediate the function of miR-223 in cardiac hypertrophy. Apoptosis repressor with CARD domain transgenic mice showed reduced hypertrophic responses. Further, we found that a circRNA HRCR functions as an endogenous miR-223 sponge to sequester and inhibit miR-223 activity, which resulted in the increase of ARC expression. Heart-related circRNA directly bound to miR-223 in cytoplasm and enforced expression of HRCR in cardiomyocytes and in mice both exhibited attenuated hypertrophic responses. These findings disclose a novel regulatory pathway that is composed of HRCR, miR-223, and ARC. Modulation of their levels provides an attractive therapeutic target for the treatment of cardiac hypertrophy and heart failure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available